Skip to main
CING
CING logo

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc. operates in a growing market, with total ADHD medication sales in the U.S. increasing approximately 8% annually since 2010, reaching about $18 billion in 2020, which reflects strong demand for ADHD treatments. The company has reported positive trial data for its lead product candidate, CTx-1301, showing efficacy compared to placebo, which potentially enhances its market position and growth prospects. Additionally, the advancement of Cingulate's proprietary precision timed-release drug delivery platform may further diversify its pipeline and create future revenue opportunities as it explores new therapeutic areas.

Bears say

Cingulate Inc reported a net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which underperformed against both internal estimates and consensus expectations. The company's financial outlook is further jeopardized by substantial risks, including liquidity concerns and potential failures in demonstrating the safety and efficacy of its product candidates during clinical trials. Additionally, the challenges of gaining regulatory approvals, securing reimbursement, and navigating competitive pressures contribute to a fundamentally negative perspective on the sustainability of Cingulate's financial performance.

Cingulate (CING) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.